A prospective observational study of biomarkers for Second-line FOLFIRI plus Aflibercept treatment in patients with metastatic colorectal cancer comparing to FOLFIRI plus beVacizumab: an Exploratory biomarker study.
Not Applicable
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000038508
- Lead Sponsor
- Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
Having an infection which needs systemic treatment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall response rate of FOLFIRI + aflibercept in patients with TAM-positive colorectal cancer.
- Secondary Outcome Measures
Name Time Method